STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 609 participants.

Also called NCT02777580

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 609 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02777580
Other papers using this trial's data
  • STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial Circulation, 2023-08-29 DOI, PubMed 37439219

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Brazil, Canada, Chile, France, Mexico, Montenegro, Russia, Serbia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02777580. Randomized; no masking; primary purpose treatment. Start 2017-08-01 (actual); primary completion 2022-10-13 (actual). Results posted on 2024-10-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction
Acronym
STREAM-2
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Clopidogrel
Intervention (Procedure)
Coronary angiography
Intervention (Procedure)
Primary PCI (percutaneous coronary intervention)
Lead sponsor
KU Leuven (class: other)
Collaborator
Boehringer Ingelheim (class: industry)
Collaborator
Life Sciences Research Partners (class: other)
Collaborator
Frans Van de Werf Fund for Clinical Cardiovascular Research (class: other)

Record details

Record id
cardio:ct-nct02777580
Content hash
f9c8fcd33045cf84566671aa6d51d91850dade8999e0afbd95762eb0169ad4d1